Pirfenidone

Pirfenidone: MedlinePlus Drug Information

Pirfenidone: learn about side effects, dosage, special precautions, and more on MedlinePlus.

Pirfenidone: Uses, Interactions, Mechanism of Action - DrugBank

Pirfenidone is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). 9,10,12 In Canada and Europe, it is approved in adults only.

Pirfenidone - Wikipedia

Pirfenidone ... Pirfenidone, sold under the brand name Pirespa among others, is a medication used for the treatment of idiopathic pulmonary fibrosis. It works by ...

Idiopathic Pulmonary Fibrosis (IPF) Treatment | Esbriet® (pirfenidone)

Learn about Esbriet® (pirfenidone), a medication for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and irreversible fibrotic ...

Pirfenidone (oral route) - Mayo Clinic

Pirfenidone is used to treat idiopathic pulmonary fibrosis. This medicine is available only with your doctor's prescription.

Esbriet (pirfenidone) dosing, indications, interactions, adverse ...

pirfenidone may work in pulmonary fibrosis has not been established. Inhibits transforming growth factor (TGF)-beta, a chemical mediator that controls many ...

Pirfenidone Oral: Uses, Side Effects, Interactions, Pictures ... - WebMD

Take this medication by mouth with food as directed by your doctor, usually 3 times a day. Taking pirfenidone with food may help decrease dizziness and nausea.

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel ...

Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in ...

Role of pirfenidone in the management of pulmonary fibrosis - PMC

Summary and conclusion. Pirfenidone has been shown to have a significant effect on FVC decline and progression-free survival in Phase III clinical trials that ...

ESBRIET® (pirfenidone) capsules, for oral use - accessdata.fda.gov

The safety of pirfenidone has been evaluated in more than 1400 subjects with over. 170 subjects exposed to pirfenidone for more than 5 years in clinical trials.

Esbriet® (pirfenidone) Dosing for Idiopathic Pulmonary Fibrosis (IPF)

Esbriet should be taken with breakfast, lunch, and dinner, allowing patients to develop habits around their mealtimes and help mitigate GI AEs.

Pirfenidone - an overview | ScienceDirect Topics

Pirfenidone is an oral drug that has anti-fibrotic and anti-inflammatory properties [2]. It can reduce the decline of absolute and percent predicted FVC and ...

Pirfenidone safety and adverse event management in idiopathic ...

One of the most effective management strategies of skin pirfenidone-related AEs is reducing sun exposure through the use of sunscreen and clothing during ...

Pirfenidone in patients with progressive fibrotic interstitial lung ...

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, ...

Pirfenidone - an overview | ScienceDirect Topics

Pirfenidone (Esbriet) is a pyridone compound given as an oral immediate-release hard capsule, thrice daily used in the treatment of idiopathic pulmonary ...

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary ...

Conclusions. Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and ...

Long-term clinical and real-world experience with pirfenidone in the ...

Pirfenidone is generally well tolerated; the most common treatment-emergent adverse events observed in clinical trials were gastrointestinal and skin-related ...

Effect of pirfenidone on lung function decline and survival: 5-yr ...

Conclusion. Our data proved that pirfenidone has a 2-yrs lasting effect on the slowing down of lung function decline, as well as on reducing ...

Pirfenidone: Uses, Dosage, Side Effects, Warnings - Drugs.com

How should I take pirfenidone? · Pirfenidone is usually taken three times a day. · Take pirfenidone with food at the same times each day. This ...

Pirfenidone in patients with unclassifiable progressive fibrosing ...

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial